tbuckley/cabot-search huggingface dataset:
Characteristics of Patients with Asthma or Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treated with Medium-Strength Inhaled Corticosteroid / Long-Acting Beta-Agonists (ICS/LABA) and Switching to High-Strength ICS/LABA or Medium-Strength Beclomethasone/Formoterol/Glycopyrronium (BDP/FF/G)
Authors: Alessio Piraino, Nicolas Roche, Alicia Gayle, Guy Brusselle, Jeffrey Shi Kai Chan, Victoria Carter, Christopher Grainge, William Henley, Luca Di Palma, Dave Singh, Derek Skinner, Adam Streeter, David Price
Journal: Journal of Allergy and Clinical Immunology (2025)
An Increase in Diastolic Blood Pressure is an Early Objective, Predictor of Allergic Reactions during Oral Food Challenges
Authors: Elizabeth Carr, Brittany Bindon, Zoe Brown, Theresa Dunham, Megan Elios, Brittany Graff, Lauren Gomez, Steve Handoyo, So Lim Kim, Sharmilee Nyenhuis, Ruchi Singla, Christina Ciaccio
Journal: Journal of Allergy and Clinical Immunology (2025)
Patients With Moderate-to-Severe Asthma Receiving Dupilumab Are More Likely to Meet 4 Key Clinical Remission Criteria: Results From the VESTIGE Trial
Authors: Mario Castro, Njira Lugogo, Alberto Papi, Celeste Porsbjerg, Christopher Brighling, Arnaud Bourdin, Cláudia Loureiro, Mei Zhang, Xavier Soler, Hashem Awad
Journal: Journal of Allergy and Clinical Immunology (2025)
Chronic urticaria in the real-life clinical practice setting followed by UCARE criteria at a private tertiary teaching hospital in Vietnam
Authors: Thanh Mai Vo, Yen Pham, Bo Nguyen, Mai Vu, Anh Nguyen, Phat Trinh, Huyen Thuc, Phuong Vo, Huong Le, Nguyet Nguyen, Oanh Hoang, Bich Nguyen, Sheryl Nunen, Timothy Craig, Hieu Chu, Dinh Nguyen
Journal: Journal of Allergy and Clinical Immunology (2025)
The Rising Prevalence of Wheezing in Iran and Associated Risk Factors
Authors: Anandu Dileep, Marjan Isfahani, Maryam Sharafkhah, Sareh Eghtesad, Roya Kelishadi, Navid Danaei, Amir Houshang Mehrparvar, Hamid Hakimi, Hossein Poustchi, Mahboobeh (maha) Mahdavinia
Journal: Journal of Allergy and Clinical Immunology (2025)
Validation of the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network Criteria and World Allergy Organization Criteria for the Diagnosis of Anaphylaxis in Children
Authors: Chayanis Leeprajong, Orathai Jirapongsananuruk, Punchama Pacharn, Witchaya Srisuwatchari, Supaluk Tangvalelerd, Kantima Kanchanapoomi
Journal: Journal of Allergy and Clinical Immunology (2025)
Association of Placental Predicted Gene Expression with Childhood-Onset Asthma
Authors: Brittney Snyder, Elizabeth Jasper, Christopher McKennan, Emma Thompson, Nathan Schoettler, Tebeb Gebretsadik, Jacklyn Hellwege, Todd Edwards, Carole Ober, Digna Velez Edwards, Tina Hartert
Journal: Journal of Allergy and Clinical Immunology (2025)
Preclinical and Pharmacokinetic Characterization of APG333: A Fully Human Monoclonal Antibody that Binds TSLP with High Affinity and Potently Inhibits Downstream Signaling
Authors: Jessica Meinke, Jacob Milligan, Mohammad Murshid Alam, Kristie Barth, Steve Raso, Grant Wickman, Joana Vidal, Jason Oh, Hussam Shaheen, Rebecca Dabora, Lukas Dillinger
Journal: Journal of Allergy and Clinical Immunology (2025)
The Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on the Pharmacokinetics and Safety of Camlipixant in Healthy Participants
Authors: Imran Satia, Anju Peters, Nathalie Chauret, Sarabjit Gahir, Denis Garceau, Roxanne Julien, Zelia Bailes, Miren Zamacona
Journal: Journal of Allergy and Clinical Immunology (2025)
Idiopathic Angioedema: Insights from a Multicenter Study in Korea
Authors: Jeongmin Lee, Mi-ae Kim, Gwang Cheon Jang, Young Min Ye, Jae-Hyuk Jang, Joo-Hee Kim, Jeong-Hee Choi, So Ri Kim, Meeyong Shin, Kyunguk Jeong, Sooyoung Lee, Taek Ki Min, Yong Won Lee, Yu Kyoung Hwang, Yoon-seok Chang
Journal: Journal of Allergy and Clinical Immunology (2025)
Single Blood Eosinophil Counts in Urban Asthmatics May Misdiagnose Eosinophilic Asthma Phenotype Leading to Misuse of Biologics
Authors: Regan Cronk, Brian Patchett, Joshua Palma, Ruchi Patel, Granit Mavraj, Ji Won Lee, Christine Song, Arash Nikjoo, Edward Schulman
Journal: Journal of Allergy and Clinical Immunology (2025)
Safety and Pharmacokinetics (PK) of BLU-808 Following Oral Dosing in Healthy Volunteers
Authors: Anitha Suram, Ivan Lee, Huilan Yao, Alexandra Grassian, Catherine Riccio, Hui Zhang, David Gan, Allen Hunt, Ronda Rippley, Wendy Ankrom
Journal: Journal of Allergy and Clinical Immunology (2025)
Time course of exacerbation reduction with extrafine beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/GB) pMDI in adults with moderate to severe asthma: A post-hoc analysis of the TRIMARAN and TRIGGER Studies
Authors: Mohammed Hanslot, Alessio Piraino, Dave Singh, Alberto Papi, Johann Virchow, G. Canonica, Laura Franzini, Andrea Vele, George Georges
Journal: Journal of Allergy and Clinical Immunology (2025)
Factors Influencing Emergency Department Readmissions and Allergy and Immunology Follow-up in Patients Presenting with Urticaria to an Urban Safety-Net Hospital
Authors: Dorde Jevtic, Gabriela Parra Riveros, Harleen Sidhu, Bobby Thomas, Yujin Jeong, Julie Kanevsky, Denisa Ferastraoaru, Manish Ramesh
Journal: Journal of Allergy and Clinical Immunology (2025)
Factors Associated with Epinephrine Administration in Pediatric Anaphylaxis
Authors: Nuha Abdulhaq, Basim Alsaywid, Connor Prosty, Christine McCusker, Adam Bretholz, Mohamed Kaouache, Ann Clarke, Judy Morris, Rodrick Lim, Edmond Chan, Ran Goldman, Andrew O'Keefe, Jennifer Gerdts, Derek Chu, Julia Upton, Elana Hochstadter, Joceyln Moisan, Xun Zhang, Jennifer Protudier, Elissa Abrams, Elinor Simons, Shira Benor, Moshe Ben-Shoshan
Journal: Journal of Allergy and Clinical Immunology (2025)
Metabolic reprogramming of macrophages by a nano-sized opsonization strategy to restore M1/M2 balance for osteoarthritis therapy
Authors: Ruijie Chen, Shimin Zheng, Xinyu Zhao, Huirong Huang, Yitianhe Xu, Chenyu Qiu, Shengjie Li, Xindan Liang, Pengfei Mao, Yuqi Yan, Yinhao Lin, Shengnan Song, Wenjing Cai, Haoxiong Guan, Yinsha Yao, Wanling Zhu, Xianbao Shi, Vadivel Ganapathy, Longfa Kou
Journal: Journal of Controlled Release (2025)
Clinico‐Genomic Interrogation of Secondary‐Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies
Authors: Jayastu Senapati, Sanam Loghavi, Jennifer Marvin‐Peek, Guillermo Garcia‐Manero, Tapan M. Kadia, Gautam Borthakur, Naval Daver, Nicholas J. Short, Nitin Jain, Ghayas C. Issa, Fadi Haddad, Danielle Hammond, Kelly Chien, Guillin Tang, Beenu Thakral, Guillermo Montalban‐Bravo, Naveen Pemmaraju, Alexandre Bazinet, Mahesh Swaminathan, Sherry Pierce, Hussein A. Abbas, Patrick Reville, Uday Popat, Elizabeth Shpall, Richard Champlin, Elias Jabbour, Farhad Ravandi, Hagop M. Kantarjian, Courtney D. DiNardo
Journal: American Journal of Hematology (2025)

Ontogeny of acute myeloid leukemia (AML) provides prognostic information, however closer interrogation with respect to AML characteristics, genomics, and various treatments are warranted. We defined untreated clinical secondary (CS) AML as AML with a diagnosis of antecedent myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm (MDS-MPN) without exposure to hypomethylating agents or chemotherapy; genomic secondary (GS) AML included patients with myelodysplasia related cytogenetics (MRC) or myelodysplasia related mutations (MRM) without a known antecedent myeloid neoplasm or prior chemo-radiotherapy for non-myeloid neoplasms. Among newly diagnosed AML patients classified as untreated CS-AML (n = 133) or GS-AML (n = 389), median relapse-free survival (RFS) (11.9 vs. 12.4 months, p = 0.36) and overall survival (OS) (11.6 vs. 14.4 months, p = 0.75) were similar. No difference in RFS and OS between these groups treated with low-intensity therapy (LIT) and venetoclax regimens was seen, but both were inferior to de novo (DN) AML without secondary-type genomics (pure DN-AML). GS-AML defined by the presence of only MRM had superior OS compared with MRM ± MRC with LIT+ venetoclax therapy (RFS 19.5 vs. 6.8 months [p < 0.01] and OS 29.6 vs. 8.4 [p < 0.01]) and had similar RFS (29.8 months, p = 0.48) and OS (32.0 months, p = 0.48) to pure DN-AML treated with LIT+ venetoclax. On multivariate analysis in patients treated with LIT+ venetoclax, untreated CS-AML (vs. GS-AML), adverse cytogenetics and ELN 2024 adverse-risk disease (mutated TP53) were associated with higher hazard of death. Adverse cytogenetics was the strongest prognostic variable predicting survival. Mutation-driven genomic ontogeny of newly diagnosed AML with MRM appears less prognostic than cytogenetic-driven ontogeny with venetoclax-based therapy.
Research trends in the use of nanobodies for cancer therapy
Authors: Jun Hou, Kejiang Du, Jinling Li, Zhenghui Li, Shaorui Cao, Shilin Zhang, Wenxing Huang, Heng Liu, Xiaomei Yang, Shuyang Sun, Shanzhao Mo, Tianyu Qin, Xilei Zhang, Shihua Yin, Xinyu Nie, Xiaoling Lu
Journal: Journal of Controlled Release (2025)
The strategy used by naïve anti-PEG antibodies to capture flexible and featureless PEG chains
Authors: Yiwei Liu, Takahiro Mori, Yusei Ito, Kimiko Kuroki, Seiichiro Hayashi, Daisuke Kohda, Taro Shimizu, Tatsuhiro Ishida, Steve R Roffler, Mika K Kaneko, Yukinari Kato, Takao Arimori, Takamasa Teramoto, Kazuhiro Takemura, Kenta Ishibashi, Yoshiki Katayama, Katsumi Maenaka, Yoshimitsu Kakuta, Akio Kitao, Takeshi Mori
Journal: Journal of Controlled Release (2025)
Precise identification of bladder tumors utilizing mucoadhesive thiolated hollow mesoporous silica nanoparticles
Authors: Yu-Chen Fa, Cheng-Che Chen, Yi-Chun Liu, Yu-Huan Lu, Xin-Hui Wang, Yen-Yu Kuo, Chia-Min Yang, Li-Chen Wu, Ja-An Annie Ho
Journal: Journal of Controlled Release (2025)
DERMATOLOGY IMAGES: SYPHILIS
Authors: Ángel González-García, Andrés Grau-Echevarría, Elena Pérez-Zafrilla, Rodrigo Peñuelas-Leal, Carolina Labrandero-Hoyos, Malena Finello, Daniel Blaya-Imbernón, Alba Nácher-Albiach, Laura Giménez-Cuenca, Jorge Magdaleno-Tapial, Esther Díez-Recio, Pablo Hernández-Bel
Journal: Journal of the American Academy of Dermatology (2025)
Enhancing biofabrication: Shrink-Resistant Collagen-Hyaluronan Composite Hydrogel for Tissue Engineering and 3D Bioprinting Applications
Authors: Kaveh Roshanbinfar, Austin Donnelly Evans, Sumanta Samanta, Maria Kolesnik-Gray, Maren Fiedler, Vojislav Krstic, Felix B Engel, Oommen P Oommen
Journal: Biomaterials (2025)
Impact of physical activity on physical function, mitochondrial energetics, ROS production, and Ca2+ handling across the adult lifespan in men
Authors: Marina Cefis, Vincent Marcangeli, Rami Hammad, Jordan Granet, Jean-Philippe Leduc-Gaudet, Pierrette Gaudreau, Caroline Trumpff, Qiuhan Huang, Martin Picard, Mylène Aubertin-Leheudre, Marc Bélanger, Richard Robitaille, José A. Morais, Gilles Gouspillou
Journal: Cell Reports Medicine (2025)

Highlights•Physical activity helps protect against age-related decline in physical performance•Physical activity boosts mitochondrial energetics while aging per se has no impact•Mitochondrial ROS production is unaffected by aging in both active and inactive men•Mitochondrial calcium handling declines with age and is linked to muscle performanceSummaryAging-related muscle atrophy and weakness contribute to loss of mobility, falls, and disability. Mitochondrial dysfunction is widely considered a key contributing mechanism to muscle aging. However, mounting evidence positions physical activity as a confounding factor, making unclear whether muscle mitochondria accumulate bona fide defects with aging. To disentangle aging from physical activity-related mitochondrial adaptations, we functionally profiled skeletal muscle mitochondria in 51 inactive and 88 active men aged 20–93. Physical activity status confers partial protection against age-related decline in physical performance. Mitochondrial respiration remains unaltered in active participants, indicating that aging per se does not alter mitochondrial respiratory capacity. Mitochondrial reactive oxygen species (ROS) production is unaffected by aging and higher in active participants. In contrast, mitochondrial calcium retention capacity decreases with aging regardless of physical activity and correlates with muscle mass, performance, and the stress-responsive metabokine/mitokine growth differentiation factor 15 (GDF15). Targeting mitochondrial calcium handling may hold promise for treating aging-related muscle impairments.Graphical abstract
Biguanides antithetically regulate tumor properties by the dose-dependent mitochondrial reprogramming-driven c-Src pathway
Authors: Jun Hyoung Park, Kwang Hwa Jung, Dongya Jia, Sukjin Yang, Kuldeep S. Attri, Songyeon Ahn, Divya Murthy, Tagari Samanta, Debasmita Dutta, Meron Ghidey, Somik Chatterjee, Seung Yeop Han, Diego A. Pedroza, Abha Tiwari, Joyce V. Lee, Caitlin Davis, Shuting Li, Vasanta Putluri, Chad J. Creighton, Nagireddy Putluri, Lacey E. Dobrolecki, Michael T. Lewis, Jeffrey M. Rosen, José N. Onuchic, Andrei Goga, Benny Abraham Kaipparettu
Journal: Cell Reports Medicine (2025)

Highlights•Biguanides activate or suppress TNBC progression in a dose-dependent manner•Biguanides regulate c-Src by the dose-dependent antithetical regulation of AMPK-FAO•Combination of dasatinib with metformin suppresses TNBC progression and metastasisSummaryThe biguanide metformin attenuates mitochondrial oxidation and is proposed as an anti-cancer therapy. However, recent clinical studies suggest increased proliferation and fatty acid β-oxidation (FAO) in a subgroup of patients with breast cancer (BC) after metformin therapy. Considering that FAO can activate Src kinase in aggressive triple-negative BC (TNBC), we postulate that low-dose biguanide-driven AMPK-ACC-FAO signaling may activate the Src pathway in TNBC. The low bioavailability of metformin in TNBC xenografts mimics metformin's in vitro low-dose effect. Pharmacological or genetic inhibition of FAO significantly enhances the anti-tumor properties of biguanides. Lower doses of biguanides induce and higher doses suppress Src signaling. Dasatinib and metformin synergistically inhibit TNBC patient-derived xenograft growth, but not in high-fat diet-fed mice. This combination also suppresses TNBC metastatic progression. A combination of biguanides with Src inhibitors provides synergy to target metastatic TNBC suffering with limited treatment options.Graphical abstract
Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the phase I/II LUPER study
Authors: Antonio Calles, Alejandro Navarro, Bernard Gaston Doger Speville Uribe, Enric Álvarez Colomé, María de Miguel, Rosa Álvarez, Marta Arregui, Víctor Moreno, Pedro Rocha, Emiliano Calvo, Jorge Ramon-Patino, Elena Corral de la Fuente, Daniel Alcalá-López, Olga Boix, Melissa Fernández-Pinto, Jose Rodríguez-Morató, Ramón Palmero, Ernest Nadal, Maria Jove, Enriqueta Felip
Journal: Journal of Thoracic Oncology (2025)
Incidence of Newly Diagnosed Cancer After Cerebral Venous Thrombosis
Authors: Anita van de Munckhof, Jamie I. Verhoeven, Ilonca C. H. Vaartjes, Nick van Es, Frank-Erik de Leeuw, Jonathan M. Coutinho
Journal: JAMA Network Open (2025)

Importance Active cancer is a risk factor for cerebral venous thrombosis (CVT), but whether CVT is associated with occult cancer is unknown. Objective To evaluate the incidence of newly diagnosed cancer after CVT. Design, Setting, and Participants This population-based cohort study used data from the Dutch Hospital Discharge Registry from January 1, 1997, to July 1, 2020. Analyses were conducted between June 2023 and April 2024. Patients admitted with a first-ever CVT were included. Patients with a history of cancer or diagnosed with cancer during hospitalization for CVT were excluded. Exposure CVT was identified using International Classification of Diseases, Ninth Revision ( ICD-9 ) and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision ( ICD-10 ) codes. Main Outcomes and Measures The main outcome was cumulative incidence of cancer after CVT. Standardized incidence ratios (SIRs) were calculated relative to a matched cohort from the general population using the Netherlands Cancer Registry. Results A total of 2649 patients with CVT (median [IQR] age, 44.5 [30.7-56.4] years; 1856 [70.1%] female) were included. Cancer was diagnosed in 119 patients during a median (IQR) follow-up of 4.7 (1.9-8.9) years, of whom 29 (24.4%) had hematologic cancer. The cumulative incidence of cancer was 5.9% (95% CI, 4.8%-7.2%) after 10 years and was highest in men aged 50 years or older (13.5%; 95% CI, 9.1%-18.7%). Patients with CVT had an increased rate of cancer compared with the reference cohort during the entire follow-up, but the difference narrowed over time (SIRs of 3.35 [95% CI, 2.41-4.55] and 1.40 [95% CI, 1.14-1.69] at 1 and 10 years, respectively). The rate was increased both in patients younger than 50 years (SIRs of 6.70 [95% CI, 3.97-10.59] and 1.72 [95% CI, 1.24-2.34] at 1 and 10 years, respectively) and those 50 years or older (SIRs of 2.41 [95% CI, 1.53-3.62] and 1.25 [95% CI, 0.96-1.60] at 1 and 10 years, respectively), as well as in male patients (SIRs of 3.59 [95% CI, 2.16-5.61] and 1.69 [95% CI, 1.25-2.23] at 1 and 10 years, respectively) and female patients (SIRs, 3.17 [95% CI, 1.99-4.80] and 1.22 [95% CI, 0.92-1.58] at 1 and 10 years, respectively). Conclusions and Relevance This cohort study of patients with CVT found an increased risk of cancer during follow-up regardless of age or sex. Men 50 years or older had the highest absolute risk, whereas younger patients had the highest relative risk. Physicians should be vigilant for signs of cancer after CVT, and further research on screening for cancer after CVT is warranted.
Transient Ischemic Attack—Not So Transient After All!
Authors: Eric E. Smith, Babak B. Navi
Journal: JAMA Neurology (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Victim-Shooter Relationships in Mass Shootings Involving Child Victims
Authors: Pamela Emengo, Jonathan D. Strope, Akanksha Sabapaty, Nolan R. Martin, Talha Rafeeqi, Ashley Stevenson, Yousof Fawzy, Stephanie D. Chao
Journal: JAMA Pediatrics (2025)

This cross-sectional study characterizes the relationships between perpetrators and victims in mass shootings that involved child victims in the US.
Cognitive Decline After First-Time Transient Ischemic Attack
Authors: Victor A. Del Bene, George Howard, Toby I. Gropen, Michael J. Lyerly, Virginia J. Howard, Russell P. Sawyer, Ronald M. Lazar
Journal: JAMA Neurology (2025)

Importance Prior research suggests reduced cognitive function after transient ischemic attack (TIA). Whether this is directly related to the TIA, a function of preexisting risk factors, or prior cognitive decline remains unclear. Objective To study if a single, diffusion-weighted image–negative, adjudicated TIA is associated with longitudinal declines in cognition, independent of preexisting risk factors. Design, Setting, and Participants This was a secondary data analysis from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, a population-based cohort following up 30 239 Black and White participants for incident cerebrovascular events. The setting consisted of telephone cognitive assessments. Participants were individuals with first-time TIA, first-time stroke, and asymptomatic community control groups with neuroimaging used for adjudication. Exposures First-time TIA and stroke. Main Outcomes and Measures Verbal fluency and memory measures administered biannually. Primary outcome was a composite standardized z score, with secondary outcomes individual test performances. Adjusted segmented regression models characterized pre-event and postevent cognition and annual cognitive change. Results Included in the study were 356 individuals with first-time TIA (mean [SD] age, 66.6 [8.7]; 188 female [53%]) and 965 individuals with first-time stroke (mean [SD] age, 66.8 [8.2]; 494 male [51%]). A total of 14 882 individuals (mean [SD] age, 63.2 [8.6] years; 8439 female [57%]) were included in the asymptomatic control group. Overall cognitive composite before index event was lower in the stroke (−0.25; 95% CI, −0.32 to −0.17) than TIA (−0.05; 95% CI: −0.17 to 0.07; P = .005) and asymptomatic (0; 95% CI, −0.03 to 0.03; P &amp;amp;lt; .001) groups. After the index event, the cognitive composite of the group with stroke significantly declined (−0.14; 95% CI, −0.21 to −0.07) compared with that of the group with TIA (0.01; 95% CI, −0.10 to 0.12; P = .02) and controls (−0.03; 95% CI, −0.05 to −0.01; P = .003). The annual decline after the index event was faster ( P = .001) in the group with TIA (−0.05; 95% CI, −0.06 to −0.03) than that for asymptomatic controls (−0.02; 95% CI, −0.02 to −0.02) but not different from the group with stroke (−0.04; 95% CI, −0.05 to −0.03; P = .43). Conclusions and Relevance Results of this cohort study suggest that despite the quick resolution of stroke symptoms in TIA, there was apparently sufficient impact to be associated with long-term cognitive decline. Whether the underlying mechanisms are by direct or secondary injury and/or interaction with concomitant neurodegenerative factors remains to be elucidated.
Pleotropic Effects of Glucose-Lowering Medications—Need for Cautious Interpretation of Target Trial Emulation Studies
Authors: Nathan M. Stall, Timothy S. Anderson, Kenneth E. Covinsky
Journal: JAMA Internal Medicine (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2025 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal